Protagonist Therapeutics (NASDAQ:PTGX) CFO Asif Ali Sells 46,203 Shares

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) CFO Asif Ali sold 46,203 shares of the company’s stock in a transaction that occurred on Tuesday, January 27th. The stock was sold at an average price of $83.13, for a total value of $3,840,855.39. Following the transaction, the chief financial officer directly owned 60,320 shares in the company, valued at $5,014,401.60. The trade was a 43.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Asif Ali also recently made the following trade(s):

• On Tuesday, January 20th, Asif Ali sold 8,588 shares of Protagonist Therapeutics stock. The shares were sold at an average price of $82.48, for a total transaction of $708,338.24.

Protagonist Therapeutics Stock Performance

Shares of Protagonist Therapeutics stock traded up $0.78 during trading hours on Tuesday, reaching $83.08. The company’s stock had a trading volume of 507,797 shares, compared to its average volume of 747,674. The stock’s fifty day simple moving average is $86.49 and its two-hundred day simple moving average is $72.41. The company has a market capitalization of $5.19 billion, a P/E ratio of 134.00 and a beta of 2.26. Protagonist Therapeutics, Inc. has a one year low of $33.70 and a one year high of $96.54.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.03). The company had revenue of $4.71 million for the quarter, compared to the consensus estimate of $5.41 million. Protagonist Therapeutics had a return on equity of 6.86% and a net margin of 21.94%. As a group, research analysts forecast that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current year.

Hedge Funds Weigh In On Protagonist Therapeutics

Hedge funds have recently modified their holdings of the company. Marshall Wace LLP bought a new position in shares of Protagonist Therapeutics during the third quarter valued at approximately $72,114,000. Commodore Capital LP purchased a new stake in Protagonist Therapeutics during the second quarter worth $59,415,000. Wellington Management Group LLP increased its holdings in shares of Protagonist Therapeutics by 83.9% in the 3rd quarter. Wellington Management Group LLP now owns 1,908,446 shares of the company’s stock valued at $126,778,000 after acquiring an additional 870,708 shares during the period. Adage Capital Partners GP L.L.C. lifted its stake in shares of Protagonist Therapeutics by 218.0% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 1,092,262 shares of the company’s stock worth $60,369,000 after purchasing an additional 748,758 shares during the last quarter. Finally, BVF Inc. IL boosted its position in Protagonist Therapeutics by 24.7% during the second quarter. BVF Inc. IL now owns 3,211,041 shares of the company’s stock valued at $177,474,000 after purchasing an additional 636,026 shares in the last quarter. Hedge funds and other institutional investors own 98.63% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on PTGX shares. Barclays increased their target price on shares of Protagonist Therapeutics from $88.00 to $108.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 17th. HC Wainwright reaffirmed a “buy” rating and set a $80.00 price objective on shares of Protagonist Therapeutics in a report on Wednesday, October 8th. Johnson Rice set a $112.00 target price on Protagonist Therapeutics in a research note on Monday, October 13th. Wedbush raised their price target on Protagonist Therapeutics from $70.00 to $86.00 and gave the company an “outperform” rating in a research report on Tuesday, October 28th. Finally, BTIG Research reiterated a “buy” rating and issued a $82.00 price objective on shares of Protagonist Therapeutics in a report on Tuesday, October 28th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $86.77.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.